CompletedNCT01503359
Sarcosine or Placebo for Schizophrenia Symptoms and Well-Being
About this title
Read the official source — NCT01503359Placebo comparisonAges 18–60Poland
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- LodzSee all locations and recruitment
Study information
Study start dateJanuary 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 70
- Sponsor
- Medical University of Lodz
- Sponsor type
- University
- Study type
- Other
- Intervention type
- Dietary supplement
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Poland
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01503359
- Official title
Show the full official title
Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Lodz
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medical University of Lodz, a university.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
